The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with...
Date First Received: March 26, 2008
Last Updated: March 26, 2008
Verified by: AstraZeneca, March 2008
Clinical Trial Phase: Phase 3 | Start Date: March 2003
Overall Status: Completed
Estimated Enrollment: 48
Brief Summary
Official Title: “A Randomized, Multicenter, Placebo and Active-Controlled, Single-Dose, 4-Period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.”
Condition Keyword(s):
Intervention(s):
The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Crossover Assignment, Efficacy Study
Study Primary Completion Date: August 2003
Intervention(s) in this Clinical Trial
- Drug: budesonide/formoterol
- Drug: fluticasone/salmeterol
- Drug: albuterol
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: 1
- budesonide/formoterol
- Active Comparator: 2
- fluticasone/salmeterol
- Active Comparator: 3
- albuterol
Outcome Measures for this Clinical Trial
Primary Measures
- FEV1 3 minutes post dose
- Time Frame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)
- Time Frame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)
Secondary Measures
- 12 hour serial FEV1
- Time Frame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)
- Time Frame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)
- Patients perception of effect
- Time Frame: Patients perception of effect
- Time Frame: Patients perception of effect
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- At least 18 years of age
- Diagnosis of asthma and baseline lung function test results as determined by the protocol
- Required and received inhaled corticosteroids within timeframe and doses specified in the protocol
Exclusion Criteria:
- Severe asthma or asthma that is markedly effected by seasonal factors
- Has required and received non-inhaled corticosteroids within the previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: AstraZeneca
Overall Clinical Trial Officials and Contacts
Catherine Bonuccelli Study Director AstraZeneca
Additional Information
Information obtained from ClinicalTrials.gov on August 29, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00646009
Study ID Number: SD-039-0733
ClinicalTrials.gov Identifier: NCT00646009
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.